



VIA EMAIL – SUBJECT: **FOR AWARENESS: Lundbeck Canada Anticipated Drug Shortage: SABRIL® (vigabatrin) powder for oral solution 500mg**

Dear Sir/Dear Madam,

I'm reaching out today on behalf of Lundbeck Canada to share some important information about an anticipated drug shortage that may affect some epilepsy patients in Canada. While you may have been made aware of this via Health Canada's drug shortages website, I wanted to make sure that we provide your organization and the epilepsy community with information directly.

Lundbeck Canada is anticipating a shortage of Sabril® (vigabatrin) powder for oral solution 500 mg. In Canada, Sabril® (vigabatrin) is indicated for the adjunctive management of partial epilepsies and the management of infantile spasms

The shortage only affects the oral powder formulation of Sabril; stock of Sabril® tablets 500 mg remains available.

This shortage is due to unexpected drug manufacturing and supply chain disruptions and is expected to begin in early August 2022. At this time, it is unknown when the powder for oral solution formulation will be back in stock. Upon learning of the anticipated shortage, Lundbeck Canada informed Health Canada, and we started informing healthcare professionals and pharmacies as of last week.

At Lundbeck, we understand how important it is for patients to have access to the medications they need. For patients and their families, we know there may be questions and concerns. We encourage all patients currently taking Sabril® powder for oral solution to consult with their healthcare professional, who can make a decision about their treatment plan.

If you have any further questions, please feel free to reach out to me at any time. If your questions are medical in nature, please see the [Canadian Sabril monograph](#) for complete product information. For additional questions and medical information enquiries, contact your healthcare professional or Lundbeck Canada Medical Information at 1-866-880-4636 or [canadamedicalinformation@lundbeck.com](mailto:canadamedicalinformation@lundbeck.com).

Regards,

Fakher Aissa  
Senior Director, Market Access  
Lundbeck Canada Inc.

Martine Hubert, MD  
Senior Director, Medical and Regulatory Affairs  
Lundbeck Canada Inc.